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There is a need to develop and validate biomarkers for treatment response and survival in 101 
tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) 102 
stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal 103 
(CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current 104 
evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC 105 
treated with NACT. 106 
 107 
METHODS 108 
We established an international collaboration to conduct a systematic review and meta-109 
analysis, pooling individual patient data from 16 sites in 11 countries. Patients had stage 110 
IIIC/IV HGSC, 3-4 NACT cycles and >6-months follow-up. Random effects models were 111 
used to derive combined odds ratios in the pooled population to investigate associations 112 
between CRS and progression free and overall survival (PFS and OS).  113 
 114 
RESULTS 115 
877 patients were included from published and unpublished studies. Median PFS and OS 116 
were 15 months (IQR 5-65) and 28 months (IQR 7-92) respectively. CRS3 was seen in 249 117 
patients (28%). The pooled hazard ratios (HR) for PFS and OS for CRS3 versus CRS1/CRS2 118 
were 0·55 (95% CI, 0·45-0·66; P <0·001) and 0·65 (95% CI 0·50–0·85, P= 0·002) 119 
respectively; no heterogeneity was identified (PFS: Q=6·42, p=0·698, I2=0·0%; OS: Q=6·89, 120 
p=0·648, I2=0·0%). CRS was significantly associated with PFS and OS in multivariate 121 
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models adjusting for age and stage. Of 306 patients with known germline BRCA1/2 status, 122 
those with BRCA1/2 mutations (n=80) were more likely to achieve CRS3 (P = 0·027).  123 
 124 
CONCLUSIONS 125 
CRS3 was significantly associated with improved PFS and OS compared to CRS1/2. This 126 
validation of CRS in a real-world setting demonstrates it to be a robust and reproducible 127 
biomarker with potential to be incorporated into therapeutic decision-making and clinical trial 128 
design.   129 
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INTRODUCTION 130 
Neoadjuvant chemotherapy (NACT) is increasingly used to treat women with tubo-ovarian 131 
high-grade serous carcinoma (HGSC) following the results of two randomised trials that 132 
demonstrated non-inferior overall survival (OS), and lower morbidity and mortality, 133 
compared to primary surgery in advanced disease.(1, 2) Interval debulking surgery (IDS) 134 
following NACT provides an opportunity to assess tumor response to antineoplastic 135 
treatments. Validated scoring systems provide prognostic information in patients with breast, 136 
esophageal, gastric and rectal cancers following neoadjuvant treatment, and are used to guide 137 
treatment decisions after surgery.(3-6) In 2015, a standardised scoring system for histological 138 
tumor regression in tubo-ovarian HGSC was proposed by Böhm and colleagues, who 139 
developed and validated a three-tier chemotherapy response score (CRS) that stratifies 140 
patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) 141 
response based on omental examination.(7) Importantly, the CRS has been shown to be 142 
reproducible amongst pathologists.(8) The International Collaboration on Cancer Reporting 143 
(ICCR) subsequently recommended the use of the CRS to assess histological NACT effect in 144 
HGSC to enable standardised and objective reporting.(9) Single institution retrospective 145 
studies have since reported an association between CRS and progression-free survival (PFS) 146 
but not OS.(10-13) These studies are limited by small sample sizes, lack of power to detect 147 
associations between CRS and OS, heterogeneity in participants, and the number of NACT 148 
cycles and regimens used. In recognition of the precedent of insufficiently validated 149 
diagnostic tools that have previously been implemented in clinical trials prematurely(14) we 150 
formed an international collaborative network to analyse pooled retrospective patient level 151 
data from several centres. This collaboration enabled meta-analysis of individual patient data 152 
(IPD) with standardised inclusion criteria that would achieve greater statistical power to 153 
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investigate the prognostic role of the CRS, with the goal of providing a sufficient level of 154 
validation that may permit use of the CRS in clinical trials.  155 
Our primary aim was to determine whether the CRS was prognostic in women with tubo-156 
ovarian HGSC treated with NACT. Secondary objectives were to investigate whether i) the 157 
CRS correlated with macroscopic residual disease at completion of interval surgery, ii) the 158 
CRS predicted platinum-resistance (as conventionally defined by disease progression <6 159 
months following last adjuvant chemotherapy cycle(15)), iii) a biochemical response in 160 
serum CA125 from diagnosis to pre-interval surgery was prognostic, and iv) patients with 161 
CRS3 had a higher frequency of pathogenic germline BRCA1/2 mutations compared to those 162 
with CRS1 and CRS2.  163 
 164 
MATERIAL AND METHODS 165 
We performed a systematic review and meta-analysis based upon a Medline and PubMed 166 
search from August 31, 2015 to June 30, 2018, with no language restrictions. This review 167 
was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-168 
Analyses (PRISMA).  169 
 170 
Ethical approval was obtained (St John of God Healthcare Human Research Ethics 171 
Committee Reference 1291) for transfer of de-identified individual patient data from 172 
participating sites for statistical analysis at the Institute for Health Research, University of 173 
Notre Dame, in Fremantle, Western Australia. Principal investigators at individual study sites 174 







SEARCH STRATEGY  181 
We used the search terms “chemotherapy response score” AND “high-grade serous ovarian 182 
carcinoma”.  A multi-centre research consortium that included 16 sites to access IPD from 183 
published and unpublished studies supplemented the search.   184 
 185 
Published studies that reported the use of the CRS in patients with stage IIIC or IV ovarian, 186 
fallopian tube, or primary peritoneal HGSC, treated by NACT and IDS, were eligible for 187 
inclusion. After removing duplicates, two authors (PC and AP) independently examined titles 188 
and then abstracts of all studies identified according to the search strategy.  The full texts of 189 
relevant abstracts were retrieved for further assessment. Uncertainties were resolved through 190 
discussion with a third author (NS). The Newcastle-Ottawa Scale and elements from the 191 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) quality 192 
assessment tool were used to assess risk of bias, with a low risk of bias considered a score of 193 
7 or more.(16, 17)  194 
Unpublished data were obtained from investigators who had previously published studies on 195 
prognostic importance of histological findings other than CRS(18-20), had presented data on 196 
CRS at international conferences, were known by the authors (NS, CBG, PC) to be from 197 
academic/tertiary referral centres and to be using CRS routinely in their clinical practice (NZ, 198 
NL, Canada, UK) and/or had expressed interest in contributing data to the meta-analysis 199 
through retrospective review and scoring of consecutive eligible cases from their centres 200 
(UK).  201 
 202 
INCLUSION AND EXCLUSION CRITERIA 203 
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Study eligibility criteria were: patients with histologically confirmed International Federation 204 
of Gynecology and Obstetrics (FIGO) 2014 stage IIIC or IV ovarian, fallopian tube, or 205 
primary peritoneal HGSC, who had received 3-4 cycles of platinum-based NACT prior to 206 
IDS and had a minimum of 6 months follow up information.  An additional criterion is 207 
implicit in the scoring system, which utilises the extent of disease in the single omental 208 
section showing the worst response to NACT, i.e. the maximum tumor load present; this is 209 
only valid in cases with documented omental disease prior to NACT. A standardised data 210 
collection tool was developed and disseminated to collect the following variables; age at 211 
diagnosis, date of first NACT cycle, date of last adjuvant chemotherapy cycle, serum CA125 212 
values prior to the first NACT cycle and before IDS, number of NACT cycles administered, 213 
FIGO stage, residual disease (surgeon’s visual assessment of completeness of the IDS 214 
categorised as no macroscopic residual disease ‘R0’, ≤1cm and >1cm), 215 
germline BRCA1/BRCA2 mutation status, and date of disease progression, death or last 216 
known follow up. Clinical and laboratory data were collected through chart and tissue 217 
repository database review. Any discrepancies were resolved by consensus and arbitration by 218 
a panel of investigators (NS, PC, AP, SB, BG, MB, CS and TM).  219 
 220 
Tumor regression scores were assigned by local gynecological pathologists at participating 221 
sites based on the omental section showing the least NACT response, as detailed in the 222 
original publication describing the CRS score (Supplementary Table 1). The original 223 
publication advised that CRS3 cases should be sub-divided into those with no residual tumor 224 
in the omentum and those with presence of residual microscopic omental tumour 225 
(Supplementary Table 1) at time of IDS.  226 
 227 
STATISTICAL ANALYSIS 228 
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Statistical analysis was performed using Stata 15.0 (Stata Statistical Software Release 15; 229 
StataCorp LP, College Station, TX). Statistical significance was determined as a P value less 230 
than 0·05 for all hypothesis tests. Random IPD meta-analysis methods were used to assess 231 
PFS and OS. Hazard ratios (HR), odds ratios (OR) and their 95% confidence intervals (CI) 232 
were calculated and reported. Tests for heterogeneity were conducted and the I2 statistic was 233 
calculated to quantify the degree of heterogeneity between sites. Time-to-event analysis was 234 
performed using Cox proportional hazard regression models to investigate factors associated 235 
with PFS and OS. PFS was defined as the date of the first NACT cycle to disease 236 
progression, as per the Gynecologic Cancer Intergroup CA125 criteria(15) or radiological 237 
progression or death, whichever occurred first. OS was defined as the date of first NACT 238 
cycle to date of death or date of last known follow-up. In the presence of non-proportional 239 
hazards, a parametric Weibull regression model was used. Evidence of non-proportionality 240 
was assessed using PHTEST at the 5% level. PFS and OS for CRS3 were compared to 241 
CRS1/CRS2 combined7. Variables included in the models were age at diagnosis (years), 242 
disease stage, and completeness of IDS. The CA125 response and germline BRCA1/2 243 
mutation status were included in subsequent models. Violation of the proportional hazard 244 
assumption for the Cox model was tested using Schoenfeld residuals. The Harrell’s C statistic 245 
was used to measure the performance of the survival models in discriminating overall PFS 246 
and OS to quantify the value of CA125 reduction (from baseline to pre-IDS) when assessed 247 
with clinicopathological factors.  248 
 249 
Chi-square and Fisher exact tests were used to examine group differences between CRS and 250 
other categorical clinical variables. A multivariate logistic regression was performed to 251 
investigate the prognostic significance of CRS with surgical residual disease, platinum 252 
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resistance, defined as disease progression <6 months after the last chemotherapy cycle, and 253 
germline BRCA1/2 mutation status.  254 
 255 
RESULTS 256 
We retrieved 6 published papers and 5 met the inclusion criteria (7, 10-13). 1 duplicate was 257 
removed (Figure 1). Risk of bias assessments are shown in Supplementary Table 2. Data 258 
were available for 1365 patients from 11 countries (Figure 1 and Supplementary Table 3). 259 
After exclusion of 488 patients who did not meet inclusion criteria, the final cohort 260 
comprised 877 patients (Figure 1). Patient characteristics, details of NACT and 261 
clinicopathological outcomes are presented in Table 1 and Supplementary Table 3. Of the 262 
sites that were able to provide complete data for CRS 3 cases (n = 202) information was 263 
available regarding anatomical site/presence of residual viable tumor after IDS for 100 cases; 264 
these were derived from 8 study sites, which collectively contributed 411 cases. Of these 32 265 
(32%) were CRS 3 with no residual tumor in the omentum; notably only 11 of these cases 266 
(11/411; 2.7%) showed a complete pathological response (i.e. no residual tumor at any 267 
site based on histopathological assessment), as the remainder showed residual disease at sites 268 
other than the omentum. Frequencies of the CRSs reported by each country varied 269 
significantly (P <0·001).  270 
 271 
677 of 877 (77·2%) patients developed recurrent disease. Median PFS was 14·9 months (IQR 272 
5.4-65.2; Supplementary Table 3). The pooled hazard ratio (HR) for PFS (CRS3 compared to 273 
CRS1/CRS2) was 0·55 (95%CI, 0·45 - 0·66; P <0·001; Figure 2).  No heterogeneity 274 
(statistical difference in reporting of CRS and PFS between countries) was identified 275 
(Q=6·42, p=0·698, I2=0·0%). In a Cox model adjusting for age, stage and residual disease at 276 
IDS, CRS and residual disease were significantly associated with PFS. CRS1/2 combined 277 
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were significantly associated with worse PFS compared to CRS3 (HR, 1·90; 95%CI, 1·58 - 278 
2·28; P <0·001; Table 2). Patients with any residual disease were at increased risk of 279 
progression independent of CRS scores (Table 2, Supplementary Figure 1). A sub-group 280 
analysis of patients with CRS3 showed the presence of residual disease in the omentum vs. 281 
no residual omental disease to be associated with an increased risk of progression (HR, 1·94; 282 
95%CI, 1·34 - 2·80; P <0·001; Supplementary Table 4, Supplementary Figure 3 and 4). 283 
 284 
There were 407 deaths. The pooled HR for OS (CRS3 compared to CRS1/CRS2) was 0·65 285 
(95%CI 0·50 – 0·85, P= 0·002; Figure 2). No heterogeneity was identified (Q=6·89, 286 
p=0·648, I2=0·0%). In a multivariate survival model that compared CRS3 with CRS1 and 287 
CRS2 combined, CRS1/2 were associated with significantly worse OS (HR, 1·73; 95%CI, 288 
1·35 - 2·25; P <0·001; Table 2). Older age at diagnosis (P= 0·032) and residual disease at 289 
completion of IDS (> 0cm and  1cm v R0; HR, 1·49; 95% CI, 1·19 - 1·85; P <0·001; >1cm 290 
vs. R0; HR, 2.30; 95% CI, 1·71 - 3·08, P <0.001) were associated with worse OS (Table 3, 291 
Supplementary Figure 2).  A sub-group analysis of patients with CRS3, showed the presence 292 
of residual disease in the omentum vs. no residual omental disease to be associated with 293 
worse OS (HR, 2·25; 95%CI, 1·31 - 3·87; P= 0·003; Supplementary Table 4, Supplementary 294 
Figure 3 and 4). 295 
 296 
Because residual disease has consistently been shown to be the most important prognostic 297 
factor in women with tubo-ovarian HGSC, we performed a subgroup analysis of the 508 298 
women debulked to R0 (Supplementary Table 5). In this group of patients CRS was 299 
significantly associated with PFS (CRS1/CRS2 vs. CRS3: HR, 1·81; 95%CI, 1·43 – 2·29; P 300 
<0·001; Supplementary Table 6) and OS (CRS1/CRS2 vs. CRS3: HR, 1·50; 95%CI, 1·08 – 301 
2·09; P=0·017; Supplementary Table 6). 302 
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 303 
Data on CA125 response to NACT were available for 809 patients. Median pre-treatment 304 
levels were 1,073 kU/L (range, 4 – 52,785 kU/L). Overall, 7 (1.0%) patients did not show 305 
any reduction in their CA125 values from baseline to pre-IDS (4 had CRS1, 2 had CRS2 and 306 
1 had CRS3). Two patients had CA125 values within the normal range at the start of 307 
treatment that did not alter (1 had CRS2 and 1 had CRS3). There were 774 patients who had 308 
a CA125 reduction of  50% and 565 patients who had a CA125 reduction of 90% from 309 
baseline to pre-IDS levels. CA125 response was not found to be a reliable prognostic factor 310 
for PFS (Harrell's C = 0·6092) or OS (Harrell's C = 0·6257) (Supplementary Table 7) and did 311 
not predict residual disease at completion of IDS (HR, 0·93; 95%CI, 0·69 – 1·29; P= 0·696).  312 
 313 
80 patients had a germline BRCA1/2 mutation (8 had CRS1, 39 had CRS2 and 33 had CRS3). 314 
226 patients had no germline BRCA1/2 mutation and BRCA status was unknown in 571 315 
patients. Patients with BRCA1/2 mutations were more likely to have a CRS3 compared to 316 
those who were BRCA1/2 wild type (P = 0·027) and were less likely to have recurrence (P = 317 
0.025, Supplementary Table 8) or to be deceased (p = 0.036, Supplementary Table 8).   318 
 319 
The outcomes for residual disease at IDS by study are presented by CRS in Supplementary 320 
Table 5 (P<0·001). Complete resection (R0) was achieved in 72·6% of patients (178 of 245) 321 
with CRS3 and 53·6% (330 of 616) patients with CRS1/CRS2 combined (P<0·001; 322 
Supplementary Table 5). In a logistic regression model that adjusted for age, FIGO stage and 323 
CRS, residual disease was significantly more likely in patients with CRS1/CRS2 compared to 324 
those with CRS3 (HR, 2·36; 95%CI, 1·70 - 3·27; P <0·001).  325 
 326 
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206 patients recurred in the platinum-resistant timeframe; 85·4% had CRS1/CRS2 and 14·6% 327 
had CRS3 (P <0·001, Supplementary Table 9). A multivariate logistic regression model 328 
showed the likelihood of platinum-resistance was significantly higher in patients with 329 
CRS1/CRS2 compared with those with CRS3 (HR, 2·62; 95%CI, 1·62 - 4·22; P <0·001) and 330 




This study showed that CRS was significantly associated with PFS and OS in multivariate 335 
analyses that adjusted for established ovarian cancer prognostic factors. Consistent with these 336 
findings, the CRS predicted surgical residual disease, platinum resistance, and germline 337 
BRCA1/2 mutation status, which are all independently associated with survival. Despite the 338 
limitations of this study, discussed below, this is a real-world demonstration of the 339 
applicability and performance of CRS in routine clinical practice, outside the confines of a 340 
highly controlled clinical trial setting.  341 
 342 
In terms of its prognostic significance the CRS system is a three tier score, with CRS3 343 
characterizing a patient cohort with favourable outcomes. Analysis of CRS3 by absence of 344 
residual omental disease vs. presence of residual microscopic omental disease suggests that 345 
CRS3 separates into two prognostic sub-groups with the former being associated with 346 
improved PFS and OS as compared to the latter. Notably CRS3 with no residual disease in 347 
the omentum does not equate to what is generally considered a complete pathological 348 
response, i.e. no residual tumor at any site; only 11/32 (34%) of cases with no residual 349 
tumour in the omentum showed absence of tumour at all other sites. The differences observed 350 
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for PFS and OS between CRS1 and CRS2 were not statistically significant. The subdivisions 351 
of both CRS3 and this less favourable prognostic group of CRS1/CRS2 using more objective 352 
parameters than morphology alone, including genomics and assessment of immune cell 353 
infiltration, should be the subject of future studies.   354 
 355 
Comparison of CRS scores between countries also demonstrates variability between 356 
proportions of cases showing CRS1/CRS2 versus CRS3. A previous study on reproducibility 357 
of CRS assignment between pathologists from different centres, and with different levels of 358 
experience, showed that training using the online tool and the original paper were sufficient 359 
to produce reproducible scoring of the same histological sections, with exceptionally high 360 
agreement in cases scored as CRS3 (kappa value 0.926).(7, 8) For this reason, we believe it is 361 
unlikely that the difference in proportion of CRS3 cases is related to interobserver variation 362 
in scoring. We chose not to include central review of cases because of the previous 363 
demonstration of reproducibility(8) and because our aim was to determine how well CRS 364 
performs as a prognostic biomarker in different centres worldwide as used by local 365 
pathologists, rather than with the incorporation of any centralised arbitration. The similarity 366 
in outcome prediction for CRS1/CRS2 vs. CRS3 across countries suggests that the scoring 367 
system is being applied as devised. A possible explanation for the observed difference 368 
between countries is variation in case selection at two decision points: the decision to offer 369 
NACT as opposed to primary surgery, and subsequently the decision to carry out IDS after 3-370 
4 NACT cycles. Both are highly dependent on local surgical oncological practices, which 371 
vary widely.(1) Whilst it is probable that all patients given NACT who showed an excellent 372 
radiological and biochemical response would proceed to IDS, there would be some variation 373 
in the proportion of poor responders who would be offered IDS, based on the subjective 374 
assessment of likelihood of achieving complete or <1cm resection of all macroscopic disease. 375 
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Other possible explanations could be the proportion of cases excluded due to loss to follow-376 
up, which could diminish the numbers of poor responders, and variations in chemotherapy 377 
schedule and dose intensity. 378 
 379 
The CRS was associated with pathogenic germline BRCA1/2 mutations, which validates 380 
BRCA1/2 mutations as a predictive marker of platinum response.(24, 25) Importantly we 381 
observed a significant association between CRS1/CRS2 and disease progression within 6 382 
months. The HGSC cases with CRS3 are enriched for BRCA1/2 mutations, and likely for 383 
other homologous DNA repair pathway defects, and we hypothesise that those cases with 384 
CRS1/CRS2 will contain a higher proportion of CCNE1-amplified tumors of the C1 385 
mesenchymal subtype, and characterized by fold-back inversions and other molecular 386 
markers of poor prognosis.(26) This would require confirmation in large prospective studies 387 
but suggests that CRS could be used to identify patients who might benefit from alternative 388 
therapeutic strategies.   389 
 390 
It is notable that in the current meta-analysis CA125 response did not predict survival, CRS 391 
or surgical residual disease in patients who showed a sufficient response to NACT to undergo 392 
IDS.  393 
 394 
Our study has several limitations that should be acknowledged. All included studies were 395 
retrospective cohorts and our multivariate analysis did not adjust for patient comorbidities 396 
and performance status. We did not monitor patient selection from contributing centres and 397 
this could have resulted in selection bias. There was no central pathology review and it is 398 
conceivable that subjective interpretation led to reported CRS values that might have 399 
misclassified some cases. Residual disease at IDS relied upon the surgeon’s report, which is 400 
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notoriously unreliable and may have biased our findings.(27) Time from completion of 401 
NACT to initiation of post-operative adjuvant treatment has recently been shown to influence 402 
survival;(28) we did not collect this information, and it is possible that variation in this time 403 
interval introduced bias.  404 
 405 
It is acknowledged that many factors contribute to the timing and pattern of disease relapse, 406 
such as the frequency of diagnostic procedures and follow-up intervals, diagnostic methods 407 
and tools used, residual disease volume and location, rate of tumor growth, differences in 408 
therapy and acquired platinum resistance. The evaluation of tumor response based only on 409 
omental disease does not take into account possible impact of tumor heterogeneity. These 410 
differences notwithstanding, the CRS provides an objective measure and biological readout 411 
of the response to NACT, which appears to encapsulate all of the aforementioned parameters 412 
and their complex interplay. 413 
 414 
Strengths of our study are the large sample that included IPD from 16 centres in 11 countries 415 
and a meta-analysis that utilised published and unpublished studies with minimal 416 
heterogeneity. The main strength of this study is the demonstration of a strong and plausible 417 
association of CRS with NACT outcome and survival in a real-world, heterogeneous study 418 
population. 419 
 420 
A Society of Gynecologic Oncology White Paper on an FDA Ovarian Cancer Clinical Trial 421 
Endpoints Workshop held in 2015 highlighted the potential of NACT response to act as a 422 
platform for biomarker discovery and regulatory approval of novel therapies.(29) However, 423 
despite strong support it was felt further work was required. The White Paper highlighted 424 
unanswered questions that included the true prevalence of complete pathological response in 425 
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patients treated by NACT, and whether pathological response should be a surrogate for PFS 426 
and/or OS. The current study provides provisional answers to these questions: the prevalence 427 
of CRS3 in 877 women treated by NACT who went on to IDS was 28% and CRS would 428 
appear to be a surrogate for both PFS and OS, independent of other known prognostic factors. 429 
In the publication by Böhm and colleagues that described and validated the CRS, histological 430 
regression in the primary adnexal tumor did not stratify patients into prognostic groups and 431 
adnexal response scores showed inferior reproducibility; in contrast, omental scores were 432 
prognostic and reproducible.(7) In the current study we were not able to assess histological 433 
regression in the adnexa or at other metastatic sites in all patients, and so it is uncertain 434 
whether our findings translate to all tissues and compartments such as visceral and 435 
diaphragmatic metastases, or retroperitoneal lymph nodes. Our results do however show that 436 
a complete or near complete pathological response in omental tumor alone (CRS3) is a 437 
biomarker for survival. 438 
 439 
Our findings require prospective validation. However, based on our results we recommend 440 
that the CRS be incorporated as an endpoint in clinical trials of novel therapeutic agents that 441 
have a NACT arm, and that CRS3 continue to be further classified with respect to the 442 
presence or absence of microscopic residual disease in the omentum. If confirmed in 443 
prospective studies, the CRS represents an appealing primary endpoint in clinical trials as a 444 
surrogate for survival because it can be measured earlier. Of note, the CRS is the primary 445 
endpoint in iPRIME, an ongoing phase II study of Durvalumab plus Tremelimumab in 446 
combination with NACT in newly diagnosed women with HGSC 447 
(ACTRN12618000109202). Furthermore, the CRS offers an opportunity to personalise 448 
treatment and may transform future clinical trial design, by stratifying treatment according to 449 
CRS following IDS. Future research should focus on the development of a statistical model 450 
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to predict prognosis that incorporates the CRS with radiological and biochemical response, 451 
surgical outcome, tumor immune profile and molecular classification. 452 
 453 
The CRS could provide clinically useful information to estimate a patient´s probability of 454 
early vs. late relapse. Most of the patients who will not relapse at five years show CRS3, 455 
making these women with no or minimal residual disease an attractive group for an 456 
additional adjuvant therapeutic agent such as poly (adenosine diphosphate–ribose) 457 
polymerase (PARP) inhibitors, that prolong PFS and could result in more cures, as shown in 458 
the recently published SOLO1 trial of maintenance Olaparib in epithelial ovarian cancer 459 
patients with BRCA1/2 mutations.(30) In contrast, patients whose tumors are found to have 460 
CRS1/2 will likely experience recurrence within 5 years; given this poor prognosis these 461 
patients could enter immediately into trials of new therapy.   462 
 463 
In summary, in this IPD meta-analysis of 877 patients, the CRS was significantly associated 464 
with PFS and OS in women with tubo-ovarian HGSC treated by NACT. This biomarker is 465 
now sufficiently validated that it can be incorporated into prospective clinical trial design to 466 
assess its potential to guide therapeutic decision-making.  467 
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